(Q37238720)

19 August 2017

Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development (English)

1 reference

19 August 2017

0 references

6

Roy S Herbst

1 reference

Vassiliki Papadimitrakopoulou

19 August 2017

5

object named as

Vassiliki A Papadimitrakopoulou

1 reference

19 August 2017

Xuemin Gu

1

1 reference

19 August 2017

Nan Chen

2

1 reference

19 August 2017

Caimiao Wei

3

1 reference

19 August 2017

Suyu Liu

4

1 reference

19 August 2017

J Jack Lee

7

1 reference

19 August 2017

4 December 2014

1 reference

Statistics in biosciences

19 August 2017

1 reference

19 August 2017

8

1 reference

19 August 2017

1

1 reference

19 August 2017

99-128

1 reference

Bayesian clinical trials in action

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5014437

The BATTLE trial: personalizing therapy for lung cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5014437

Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5014437

Design of clinical trials for biomarker research in oncology

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5014437

Drug development and clinical trials--the path to an approved cancer drug

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5014437

Role of randomized phase III trials in an era of effective targeted therapies

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5014437

Adaptive clinical trials in oncology

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5014437

Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5014437

Hallmarks of Cancer: The Next Generation

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5014437

An accelerated pathway for targeted cancer therapies.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5014437

Outcome--adaptive randomization: is it useful?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5014437

Bayesian adaptive randomization designs for targeted agent development

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5014437

Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5014437

Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5014437

Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5014437

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5014437

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5014437

Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5014437

6 September 2017

Bayesian clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5014437

Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5014437

Chemotherapy in stage-IV NSCLC.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5014437

Can the pharmaceutical industry reduce attrition rates?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5014437

The price of innovation: new estimates of drug development costs

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5014437

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5014437

Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5014437

Worth adapting? Revisiting the usefulness of outcome-adaptive randomization

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5014437

Drug development: portals of discovery

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5014437

Early accelerated approval for highly targeted cancer drugs.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5014437

A Bayesian adaptive design with biomarkers for targeted therapies

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5014437

Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5014437

Ethical issues in oncology biostatistics.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5014437

3 September 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12561-014-9124-2

Adaptive clinical trials: the promise and the caution

21 January 2018

1 reference

12 December 2020

Biomarker as a classifier in pharmacogenomics clinical trials: a tribute to 30th anniversary of PSI

1 reference

12 December 2020

Drug approvals 2011: focus on companion diagnostics

1 reference

12 December 2020

Clinical application of pharmacogenetics

1 reference

12 December 2020

10.1007/S12561-014-9124-2

Identifiers

DOI

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

27617040

1 reference